BAMBUTEROL

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H29N3O5
Molecular Weight	367.4407
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)NCC(c1cc(cc(c1)OC(=O)N(C)C)OC(=O)N(C)C)O

InChI

InChIKey=ANZXOIAKUNOVQU-UHFFFAOYSA-N

InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24277179
Curator's Comment:: Description was created based on several sources, including https://www.medicines.org.uk/emc/medicine/9574 | http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf | https://www.ncbi.nlm.nih.gov/pubmed/2906603

Bambuterol is an active precursor of the selective beta2-adrenergic agonist terbutaline. Bambuterol is the bis-N,N-dimethyl-carbamate of terbutaline. Bambuterol is a remarkably selective and potent inhibitor of cholinesterase. BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-2 adrenergic receptor 197 Target ID: CHEMBL210 Sources: https://www.medicines.org.uk/emc/medicine/9574	Agonist 2451
Butyrylcholinesterase 36 Target ID: CHEMBL1914 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2906603 \| https://www.ncbi.nlm.nih.gov/pubmed/25504505	Inhibitor 7687		17.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic obstructive pulmonary disease 174 Sources: https://www.medicines.org.uk/emc/medicine/9574 http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf	Primary		Approved 7968	BAMBEC Approved Use BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.
Asthma 226 Sources: https://www.medicines.org.uk/emc/medicine/9574 http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf	Primary		Approved 7968	BAMBEC Approved Use BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.

PubMed

Title	Date	PubMed
Bambuterol and terbutaline in human cerebrospinal fluid and plasma.	1993	8223836

Patents

Sample Use Guides

In Vivo Use Guide

BAMBEC (Bambuterol hydrochloride) Tablets 10 mg. The recommended starting doses are 10 mg–20 mg. The 10 mg dose may be increased to 20 mg if necessary after 1–2 weeks, depending on the clinical effect. In patients who have previously tolerated beta2-agonists well, the recommended starting dose, as well as maintenance dose, is 20 mg. BAMBEC (Bambuterol hydrochloride) oral solution 1mg/ml. The recommended initial dose is 10mg (10ml). The dose may be increased to 20mg (20ml) after 1-2 weeks, depending on the clinical effect. In patients who previously have tolerated oral beta2-agonists well, the recommended initial dose is 20mg (20ml).

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

BAMBUTEROL

Official Name

English

BAMBUTEROL [INN]

Common Name

English

BAMBUTEROL [WHO-DD]

Common Name

English

(+/-)-5-(2-(TERT-BUTYLAMINO)-1-HYDROXYETHYL)-M-PHENYLENE BIS(DIMETHYLCARBAMATE)

Systematic Name

English

BAMBUTEROL [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QR03CC12